{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "PRPO",
  "name": "Precipio, Inc.",
  "url": "https://frontierpicks.com/dossiers/PRPO/",
  "json_url": "https://frontierpicks.com/dossiers/PRPO.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Precipio’s diagnostics growth and renewed operating cash generation support a conditional recovery toward its recorded $32.37 high. A weekly close above that level confirms the price case; a weekly close below the 2026-09-11 reference close of $27.32 invalidates it.",
  "invalidation_trigger": "A weekly close below $27.32 invalidates the recovery thesis by losing the 2026-09-11 adjusted reference close; this level is a research boundary, not an established support shelf.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [],
  "body_markdown": "## Current Thesis\n\nPrecipio’s diagnostics growth and return to operating cash generation support a conditional recovery thesis: a weekly close above the recorded $32.37 high would confirm it, while a weekly close below $27.32 would invalidate it. Both market references come from the adjusted price series dated 2026-09-11.\n\nThe interpretation is that the narrative is maturing — management announced performance-option vesting on 2026-05-13, and the latest company release remains the 2026-08-14 earnings report. The September price snapshot shows positive three-month performance alongside weaker recent momentum; this does not establish expanding participation. [Company release archive](https://www.precipiodx.com/investors/press-releases/)\n\n## Bull Case\n\n- **Revenue expanded across both businesses.** In its 2026-08-14 release, Precipio reported second-quarter pathology revenue of $6.1 million versus $6.0 million in the first quarter, and product revenue of $0.9 million versus $0.66 million. [Company results](https://www.precipiodx.com/precipio-announces-q2-2026-financial-results/)\n\n- **Operations generated cash again.** The same release reported $0.7 million of second-quarter operating cash inflow and $0.4 million of adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), versus negative $0.2 million of adjusted EBITDA in the first quarter. A single quarterly recovery cannot establish durable cash generation. [Company results](https://www.precipiodx.com/precipio-announces-q2-2026-financial-results/)\n\n## Bear Case\n\n- **Revenue growth did not preserve earnings.** Benzinga’s 2026-08-14 report recorded sales of $7.021 million versus $5.654 million a year earlier, but a loss per share of $0.12 versus earnings of $0.05. The company’s reconciliation separately reported a second-quarter net loss of $0.2 million. [Company reconciliation](https://www.precipiodx.com/precipio-announces-q2-2026-financial-results/)\n\n- **Vested awards require careful interpretation.** On 2026-05-13, Precipio announced that management’s 2025 performance options had vested following the required price appreciation. Vesting is an observable compensation event; that announcement does not establish exercise, insider selling or subsequent market supply. [Company options announcement](https://www.precipiodx.com/management-teams-2025-market-based-options-have-vested/)\n\n## Setup & Price Structure\n\nThe 2026-09-11 adjusted close was $27.32, with the shares up 23.6% over three months and 15.6% below the recorded 52-week high of $32.37. The 14-period relative strength index (RSI) was 35.3. These measurements describe a retreat within a positive three-month price change; they do not establish a completed base.\n\nThe $27.32 reference close is the explicit boundary for this recovery hypothesis, not a verified historical support shelf. The supplied observations contain no moving-average level, volume history, short-interest measurement or retail-participation series. Crowding cannot be established from this evidence.\n\nThe low-conviction forecast concerns a weekly close above $32.37 before a weekly close below $27.32. The reference-close boundary and the September momentum reading limit the case despite the August operating improvement.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-13 through 2026-10-13:** No company-confirmed catalyst was identified for this window. The company’s update-call archive lists 2026-08-17 as its latest quarterly call; that event has elapsed. [Shareholder updates](https://www.precipiodx.com/investors/business-update-calls/)\n\n- **~2026-11-16, estimated:** MarketBeat estimates the next quarterly earnings release for this date; company confirmation is absent. That report would test whether the August cash-generation recovery persisted. [MarketBeat earnings calendar](https://www.marketbeat.com/earnings/reports/2026-8-14-precipio-inc-stock/)\n\n## What Would Change Our Mind\n\nFailure to retain the September reference close would end the published recovery case: a weekly close below $27.32 is the observable invalidation. This is a price-thesis boundary, not proof that the underlying business has deteriorated.\n\nA return to negative quarterly operating cash flow would separately contradict the durability interpretation attached to the 2026-08-14 results. Conversely, another positive quarter would extend the evidence but would not by itself establish a lasting trend.\n\n## Correlation Notes\n\nFrontierPicks’ Medtech & diagnostics assessment moved from accelerating on 2026-08-30 to maturing on 2026-09-06 and saturated on 2026-09-13. That is a dated group assessment, not a measured correlation or a finding that Precipio itself is saturated.\n\nThe listed peers include INSP, ATRC, BFLY and TXG, but no paired return series accompanies the 2026-09-13 assessment. The sample is insufficient to claim that their price movements explain PRPO’s September structure. The single-name thesis therefore rests on its reported operations and explicit market-close conditions.",
  "first_seen": "2026-09-13",
  "last_analyzed": "2026-09-13T11:01:36+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}